# LZTR1

## Overview
LZTR1, or Leucine Zipper-like Transcription Regulator 1, is a gene that encodes a protein involved in the regulation of various cellular processes, primarily through its role as a substrate adaptor in the CUL3-based ubiquitin E3 ligase complex. The protein, leucine zipper-like post-translational regulator 1, is characterized by its modular structure, which includes Kelch motifs and BTB/POZ domains, facilitating its function in protein-protein interactions and ubiquitination pathways (Paladino2021Structural; Motta2018Dominant). LZTR1 plays a critical role in the polyubiquitination and degradation of RAS GTPases, thereby regulating the RAS/MAPK signaling pathway, which is crucial for cell growth and differentiation (Abe2019LZTR1). Additionally, LZTR1 is involved in vesicular trafficking and maintaining vascular integrity, highlighting its importance in cardiovascular function (Sewduth2020The). Mutations in the LZTR1 gene are linked to clinical conditions such as schwannomatosis and Noonan syndrome, as well as various cancers, underscoring its significance as a tumor suppressor and its involvement in developmental processes (Horn2024LZTR1; Piotrowski2013Germline).

## Structure
The LZTR1 protein is characterized by a modular structure that includes six tandemly arranged Kelch motifs at the N-terminus and two BTB/POZ domains at the C-terminus (Motta2018Dominant). The Kelch domain forms a six-bladed β-propeller structure, which is crucial for substrate recognition and interaction within the Cullin3-RING ligase E3 (CRL3) complex (Paladino2021Structural; Motta2018Dominant). This domain is composed of conserved motifs with β-strands stabilizing the backbone and loops on one face mediating protein-protein interactions (Motta2018Dominant).

The BTB domains, located at the C-terminus, consist of α-helices and short β-sheets, contributing to dimerization and interactions with Cul3 (Paladino2021Structural). These domains are involved in the protein's role as a substrate receptor for ubiquitin ligase complexes, facilitating the ubiquitination and subsequent proteasomal degradation of substrates (Paladino2021Structural; Motta2018Dominant).

LZTR1's structure is noted for its flexibility, with long flexible loops that may contribute to its functional dynamics, particularly in the regulation of biological functions such as enzyme catalysis and substrate ubiquitination (Paladino2021Structural). The protein's architecture allows it to integrate adaptor and substrate-receptor functions into a single polypeptide, which is a distinctive feature of Cul3-based ligases (Paladino2021Structural).

## Function
The LZTR1 gene encodes a protein that functions as a substrate adaptor for the CUL3-based ubiquitin E3 ligase complex, playing a crucial role in the polyubiquitination and degradation of RAS GTPases, including MRAS, HRAS, NRAS, and KRAS. This process is essential for regulating the RAS/MAPK signaling pathway, which influences cell growth and differentiation (Abe2019LZTR1; Steklov2018Mutations). LZTR1-mediated ubiquitination involves multiple types of ubiquitin chains, such as K48-linked chains that promote proteasome-mediated degradation and K63-linked chains that regulate protein functions like protein-protein interactions (Abe2019LZTR1).

In healthy cells, LZTR1 also regulates vesicular trafficking by controlling the ubiquitination of the ESCRT-III component CHMP1B, which is crucial for maintaining normal endothelial cell function and vascular integrity (Sewduth2020The). LZTR1's role in vesicular trafficking is critical for cardiovascular function, as it ensures the stability of adherent and tight junctions in endothelial cells, preventing abnormal vascular leakage (Sewduth2020The). The protein is active in the Golgi apparatus, where it modulates protein interactions and stability, contributing to its function as a tumor suppressor (Bigenzahn2018LZTR1).

## Clinical Significance
Mutations in the LZTR1 gene are associated with several clinical conditions, most notably schwannomatosis and Noonan syndrome. Schwannomatosis is characterized by the development of multiple schwannomas, which are benign nerve sheath tumors. This condition is linked to loss-of-function mutations in LZTR1, including nonsense, frameshift, and splice-site variants, and is inherited in an autosomal dominant manner (Jacquinet2020Oligoastrocytoma; Piotrowski2013Germline). LZTR1 mutations account for a significant proportion of familial and sporadic schwannomatosis cases, particularly those without SMARCB1 mutations (Jacquinet2020Oligoastrocytoma).

LZTR1 is also implicated in Noonan syndrome, a developmental disorder characterized by features such as short stature, facial dysmorphisms, and heart defects. Mutations in LZTR1 can lead to both dominant and recessive forms of Noonan syndrome, affecting the RAS/MAPK signaling pathway (Pagnamenta2019Delineation; Motta2018Dominant). These mutations can enhance RAS-MAPK signaling, contributing to the clinical manifestations of the syndrome (Motta2018Dominant).

Additionally, LZTR1 is identified as a tumor suppressor gene, with somatic mutations associated with various cancers, including glioblastoma and breast and liver cancers (Horn2024LZTR1). The gene's involvement in the RAS/MAPK pathway underscores its significance in both tumor suppression and developmental processes (Jacquinet2020Oligoastrocytoma).

## Interactions
LZTR1 interacts with several proteins, primarily as a substrate adaptor for the CUL3-based ubiquitin E3 ligase complex. It facilitates the polyubiquitination and degradation of RAS proteins, including MRAS, HRAS, NRAS, and KRAS, by forming a complex with CUL3 and these RAS proteins (Abe2019LZTR1; Steklov2018Mutations). The interaction between LZTR1 and RAS proteins is mediated through its Kelch domain, while the BTB domain of LZTR1 interacts strongly with CUL3 (Abe2019LZTR1). 

LZTR1 also interacts with RIT1, a small GTPase, particularly when RIT1 is bound to GDP, facilitating its ubiquitination and degradation (Castel2019RIT1). The interaction with RIT1 is disrupted in oncogenic mutants, leading to decreased ubiquitination and degradation of RIT1 (Castel2019RIT1). 

LZTR1's interaction with KRAS is affected by KRAS mutations, which disrupt the association and lead to altered protein stability and turnover (Damianou2021Interplay). LZTR1 also interacts with autophagy-related proteins such as SQSTM1/p62 and LC3B-II, although the contribution of autophagy to LZTR1-mediated RAS degradation is minimal (Abe2019LZTR1). These interactions are crucial for regulating RAS signaling pathways and are implicated in various diseases when disrupted.


## References


[1. (Pagnamenta2019Delineation) Alistair T. Pagnamenta, Pamela J. Kaisaki, Fenella Bennett, Emma Burkitt‐Wright, Hilary C. Martin, Matteo P. Ferla, John M. Taylor, Lianne Gompertz, Nayana Lahiri, Katrina Tatton‐Brown, Ruth Newbury‐Ecob, Alex Henderson, Shelagh Joss, Astrid Weber, Jenny Carmichael, Peter D. Turnpenny, Shane McKee, Francesca Forzano, Tazeen Ashraf, Kimberley Bradbury, Deborah Shears, Usha Kini, Anna de Burca, Edward Blair, Jenny C. Taylor, and Helen Stewart. Delineation of dominant and recessive forms of lztr1‐associated noonan syndrome. Clinical Genetics, 95(6):693–703, April 2019. URL: http://dx.doi.org/10.1111/cge.13533, doi:10.1111/cge.13533. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cge.13533)

[2. (Horn2024LZTR1) Svea Horn, Teresa Neuhann, Corina Hennig, Angela Abad-Perez, Eva-Christina Prott, Lisa Cardellini, Cornelia Potratz, Jonas Leubner, Birgit Eichhorn, Martin Merkel, Angela Abicht, and Angela M. Kaindl. Lztr1 loss-of-function variants associated with café au lait macules with or without freckling. Frontiers in Neurology, August 2024. URL: http://dx.doi.org/10.3389/fneur.2024.1391425, doi:10.3389/fneur.2024.1391425. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fneur.2024.1391425)

[3. (Jacquinet2020Oligoastrocytoma) Adeline Jacquinet, Adeline Bonnard, Yline Capri, Didier Martin, Bernard Sadzot, Elettra Bianchi, Laurent Servais, Jean-Paul Sacré, Hélène Cavé, and Alain Verloes. Oligo-astrocytoma in lztr1-related noonan syndrome. European Journal of Medical Genetics, 63(1):103617, January 2020. URL: http://dx.doi.org/10.1016/j.ejmg.2019.01.007, doi:10.1016/j.ejmg.2019.01.007. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejmg.2019.01.007)

[4. (Abe2019LZTR1) Taiki Abe, Ikumi Umeki, Shin-ichiro Kanno, Shin-ichi Inoue, Tetsuya Niihori, and Yoko Aoki. Lztr1 facilitates polyubiquitination and degradation of ras-gtpases. Cell Death &amp; Differentiation, 27(3):1023–1035, July 2019. URL: http://dx.doi.org/10.1038/s41418-019-0395-5, doi:10.1038/s41418-019-0395-5. This article has 72 citations.](https://doi.org/10.1038/s41418-019-0395-5)

5. (Damianou2021Interplay) Interplay Between KRAS and LZTR1 Protein Turnover, Controlled by CUL3/LZTR1 E3 Ubiquitin Ligase, is Disrupted by KRAS Mutations. This article has 0 citations.

[6. (Piotrowski2013Germline) Arkadiusz Piotrowski, Jing Xie, Ying F Liu, Andrzej B Poplawski, Alicia R Gomes, Piotr Madanecki, Chuanhua Fu, Michael R Crowley, David K Crossman, Linlea Armstrong, Dusica Babovic-Vuksanovic, Amanda Bergner, Jaishri O Blakeley, Andrea L Blumenthal, Molly S Daniels, Howard Feit, Kathy Gardner, Stephanie Hurst, Christine Kobelka, Chung Lee, Rebecca Nagy, Katherine A Rauen, John M Slopis, Pim Suwannarat, Judith A Westman, Andrea Zanko, Bruce R Korf, and Ludwine M Messiaen. Germline loss-of-function mutations in lztr1 predispose to an inherited disorder of multiple schwannomas. Nature Genetics, 46(2):182–187, December 2013. URL: http://dx.doi.org/10.1038/ng.2855, doi:10.1038/ng.2855. This article has 227 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ng.2855)

[7. (Steklov2018Mutations) M. Steklov, S. Pandolfi, M. F. Baietti, A. Batiuk, P. Carai, P. Najm, M. Zhang, H. Jang, F. Renzi, Y. Cai, L. Abbasi Asbagh, T. Pastor, M. De Troyer, M. Simicek, E. Radaelli, H. Brems, E. Legius, J. Tavernier, K. Gevaert, F. Impens, L. Messiaen, R. Nussinov, S. Heymans, S. Eyckerman, and A. A. Sablina. Mutations in lztr1 drive human disease by dysregulating ras ubiquitination. Science, 362(6419):1177–1182, December 2018. URL: http://dx.doi.org/10.1126/science.aap7607, doi:10.1126/science.aap7607. This article has 140 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.aap7607)

[8. (Paladino2021Structural) Antonella Paladino, Fulvio D’Angelo, Teresa Maria Rosaria Noviello, Antonio Iavarone, and Michele Ceccarelli. Structural model for recruitment of rit1 to the lztr1 e3 ligase: evidences from an integrated computational approach. Journal of Chemical Information and Modeling, 61(4):1875–1888, April 2021. URL: http://dx.doi.org/10.1021/acs.jcim.1c00296, doi:10.1021/acs.jcim.1c00296. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/acs.jcim.1c00296)

[9. (Sewduth2020The) Raj Nayan Sewduth, Silvia Pandolfi, Mikhail Steklov, Aidana Sheryazdanova, Peihua Zhao, Nathan Criem, Maria F. Baietti, Benoit Lechat, Rozeen Quarck, Francis Impens, and Anna A. Sablina. The noonan syndrome gene lztr1 controls cardiovascular function by regulating vesicular trafficking. Circulation Research, 126(10):1379–1393, May 2020. URL: http://dx.doi.org/10.1161/CIRCRESAHA.119.315730, doi:10.1161/circresaha.119.315730. This article has 28 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1161/CIRCRESAHA.119.315730)

[10. (Bigenzahn2018LZTR1) Johannes W. Bigenzahn, Giovanna M. Collu, Felix Kartnig, Melanie Pieraks, Gregory I. Vladimer, Leonhard X. Heinz, Vitaly Sedlyarov, Fiorella Schischlik, Astrid Fauster, Manuele Rebsamen, Katja Parapatics, Vincent A. Blomen, André C. Müller, Georg E. Winter, Robert Kralovics, Thijn R. Brummelkamp, Marek Mlodzik, and Giulio Superti-Furga. Lztr1 is a regulator of ras ubiquitination and signaling. Science, 362(6419):1171–1177, December 2018. URL: http://dx.doi.org/10.1126/science.aap8210, doi:10.1126/science.aap8210. This article has 151 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.aap8210)

[11. (Motta2018Dominant) Marialetizia Motta, Miray Fidan, Emanuele Bellacchio, Francesca Pantaleoni, Konstantin Schneider-Heieck, Simona Coppola, Guntram Borck, Leonardo Salviati, Martin Zenker, Ion C Cirstea, and Marco Tartaglia. Dominant noonan syndrome-causing lztr1 mutations specifically affect the kelch domain substrate-recognition surface and enhance ras-mapk signaling. Human Molecular Genetics, 28(6):1007–1022, November 2018. URL: http://dx.doi.org/10.1093/hmg/ddy412, doi:10.1093/hmg/ddy412. This article has 66 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddy412)

[12. (Castel2019RIT1) Pau Castel, Alice Cheng, Antonio Cuevas-Navarro, David B. Everman, Alex G. Papageorge, Dhirendra K. Simanshu, Alexandra Tankka, Jacqueline Galeas, Anatoly Urisman, and Frank McCormick. Rit1 oncoproteins escape lztr1-mediated proteolysis. Science, 363(6432):1226–1230, March 2019. URL: http://dx.doi.org/10.1126/science.aav1444, doi:10.1126/science.aav1444. This article has 70 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.aav1444)